Siegel R L, Miller K D, Jemal A. Cancer statistics [J]. CA-Cancer J Clin, 2019,69(1):7-34.
[2]
Ishino Y, Shinagawa H, Makino K, et al. Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product [J]. J Bacteriol, 1987, 169(12):5429-5433.
[3]
Jinek M, Chylinski K, Fonfara I, et al. A programmable Dual-RNA-Guided DNA endonuclease in adaptive bacterial immunity [J]. Science, 2012, 337(6096):816-821.
[4]
Osborn M J,Belanto J J, Tolar J, et al. Gene editing and its application for hematological diseases [J]. Hematol, 2016, 104(1):18-28.
[5]
Barrangou, R, Fremaux, C, Deveau, H, et al. CRISPR provides acquired resistance against viruses in prokaryotes [J]. Science, 315(5819):1709-1712.
[6]
Cong L, Ran F A, Cox D, et al. Multiplex genome engineering using CRISPR/Cas systems [J]. Science, 2015, 339(11):197-208.
[7]
Mali P, Yang L, Esvelt K M, et al. RNA-guided human genome engineering via Cas9 [J]. Science, 2013, 339(6121):823-826.
Watanabe S, Shimada S, Akiyama Y, et al. Loss of KDM6A characterizes a poor prognostic subtype of human pancreatic cancer and potentiates HDAC inhibitor lethality [J]. Int J Cancer, 2019, 145(1):192-205.
[10]
Pessolano E, Belvedere R, Bizzarro V, et al. Annexin A1 may induce pancreatic cancer progression as a key player of extracellular vesicles effects as evidenced in the in vitro MIA PaCa-2 model system [J]. Int J Mol Sci, 2018, 19(12): 3878-3890.
[11]
Belvedere R, Bizzarro V, Forte G, et al. Annexin A1 contributes to pancreatic cancer cell phenotype, behaviour and metastatic potential independently of Formyl Peptide Receptor pathway [J]. Sci Rep, 2016, 6:296-316.
[12]
Barkeer S, Chugh S, Karmakar S, et al. Novel role of O-glycosyl transferases GALNT3 and B3GNT3 in the self-renewal of pancreatic cancer stem cells [J].BMC Cancer, 2018, 18:1157-1170.
[13]
Chugh S,Barkeer S,Rachagani S,et al. Disruption of C1galt1 gene promotes development and metastasis of pancreatic adenocarcinomas in mice [J]. Gastroenterology, 2018, 155(5):1608-1624.
[14]
Li W, Xu H, Xiao T, et al. MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens [J]. Genome Biol, 2014, 15(12):554.
[15]
He Y, Ye M, Zhou L, et al. High Rab11-FIP4 expression predicts poor prognosis and exhibits tumor promotion in pancreatic cancer [J]. Int J Oncol, 2017, 50(2):396-404.
[16]
Muzumdar M D, Chen P Y, Dorans K J, et al. Survival of pancreatic cancer cells lacking KRAS function [J]. Nat Commun, 2017, 8(1):1090.
[17]
Zhang D, Li L, Jiang H, et al. Constitutive IRAK4 activation underlies poor prognosis and chemoresistance in pancreatic ductal adenocarcinoma [J]. Clin Cancer Res, 2016, 23(7):1748-1759.
[18]
Shuiliang Y, Neetha P, Ming L, et al. CRABP-Ⅱ enhances pancreatic cancer cell migration and invasion by stabilizing interleukin 8 expression [J]. Oncotarget, 2017, 8(32):52432-52444.
[19]
Harada T, Yamamoto H, Kishida S, et al. Wnt5b-associated exosomes promote cancer cell migration and proliferation [J]. Cancer Sci, 2017, 108(1):42-52.
[20]
Lal S, Cheung E C, Zarei M, et al. CRISPR knockout of the HuR gene causes a xenograft lethal phenotype [J]. Mol Cancer Res, 2017, 15(6):696-707.
[21]
Michael A, O’Sullivan E, Anne M D, et al. IL2RG, identified as overexpressed by RNA-seq profiling of pancreatic intraepithelial neoplasia, mediates pancreatic cancer growth [J]. Oncotarget, 2017, 8(48):83370-83383.
[22]
Santoro R, Zanotto M, Carbone C, et al. MEKK3 sustains EMT and stemness in pancreatic cancer by regulating YAP and TAZ transcriptional activity [J]. Anticancer Res, 2018, 38(4):1937-1946.
[23]
Watanabe S, Shimada S, Akiyama Y, et al. Loss of KDM6A characterizes a poor prognostic subtype of human pancreatic cancer and potentiates HDAC inhibitor lethality[J]. Int J Cancer, 2018, 145(1):192-205.
[24]
Pessolano E, Belvedere R, Bizzarro V, et al. Annexin A1 may induce pancreatic cancer progression as a key player of extracellular vesicles effects as evidenced in the in vitro MIA PaCa-2 model system [J]. Int J Mol Sci, 2018, 19(12):e 3878.
[25]
Yuza K, Nakajima M, Nagahashi M, et al. Different roles of sphingosine kinase 1 and 2 in pancreatic cancer progression [J]. J Surg Res, 2018, 232:186-194.
[26]
Barkeer S, Chugh S, Karmakar S, et al. Novel role of O-glycosyltransferases GALNT3 and B3GNT3 in the self-renewal of pancreatic cancer stem cells [J]. BMC Cancer, 2018, 18(1):1157
[27]
Chugh S, Barkeer S, Rachagani S,et al. Disruption of C1galt1 gene promotes development and metastasis of pancreatic adenocarcinomas in mice [J]. Gastroenterology, 2018, 155(5):1608-1624.
[28]
Wang SC, Nassour I, Xiao S, et al. SWI/SNF component ARID1A restrains pancreatic neoplasia formation [J]. Gut, 2019, 68(7):1259-1270.
[29]
Bin L, Hai Y, Christian P, et al. The effect of GPRC5a on the proliferation, migration ability, chemotherapy resistance, and phosphorylation of GSK-3β in pancreatic cancer [J]. Int J Mol Sci, 2018, 19(7):e1870.
[30]
Liu B, Yang H, Taher L, et al. Identification of prognostic biomarkers by combined mRNA and miRNA expression microarray analysis in pancreatic cancer [J]. Transl Oncol, 2018, 11(3):700-714.
[31]
Kohei Y, Tetsuhide I, Masami M, et al. Using CRISPR/Cas9 to knock out amylase in acinar cells decreases pancreatitis-induced autophagy [J]. Biomed Res Int, 2018, 2018:1-8.
[32]
Stock K, Borrink R, Mikesch J H, et al. Overexpression and Tyr421-phosphorylation of cortactin is induced by three-dimensional spheroid culturing and contributes to migration and invasion of pancreatic ductal adenocarcinoma (PDAC) cells [J]. Cancer Cell Int, 2019, 19(1): 77.
[33]
Abdalla M Y, Ahmad I M, Rachagani S, et al. Enhancing responsiveness of pancreatic cancer cells to gemcitabine treatment under hypoxia by Heme Oxygenase-1 inhibition [J]. Transl Res, 2019, 207(5):56-69.
[34]
Liu X, Huang Y, Yuan H, et al. Disruption of oncogenic liver-intestine cadherin (CDH17) drives apoptotic pancreatic cancer death [J]. Cancer Lett, 2019, 454(10):204-214.
[35]
Hwang M, Jun D W, Kang E H, et al. EI24, as a component of autophagy, is involved in pancreatic cell proliferation [J]. Front Oncol, 2019,9:652.
[36]
Abdalla M , Ahmad I, Rachagani S, et al. Enhancing responsiveness of pancreatic cancer cells to gemcitabine treatment under hypoxia by Heme Oxygenase-1 inhibition [J]. Transl Res, 2019, 207(5):56-69.
[37]
Li M, Xie H, Liu Y, et al. Knockdown of hypoxia-inducible factor-1 alpha by tumor targeted delivery of CRISPR/Cas9 system suppressed the metastasis of pancreatic cancer [J]. J Control Release, 2019, 304:204-215.
[38]
Bakke J, Wright WC, Zamora AE, et al. Genome-wide CRISPR screen reveals PSMA6 to be an essential gene in pancreatic cancer cells [J]. BMC Cancer, 2019, 19 (1):253-273.
[39]
Steinhart Z, Pavlovic Z, Chandrashekhar M, et al. Genome-wide CRISPR screens reveal a Wnt-FZD5 signaling circuit as a druggable vulnerability of RNF43-mutant pancreatic tumors [J]. Nat Med. 2017, 23(1):60-68.
[40]
Wang B, Krall E B, Aguirre A, et al. ATXN1L, CIC, and ETS transcription factors modulate sensitivity to MAPK pathway inhibition [J]. Cell Rep, 2017, 18(6):1543-1557.
[41]
Marie R, Marine L, Fabian G, et al. Gene therapy for pancreatic cancer: specificity, issues and hopes [J]. Int J Mol Sci, 2017, 18(6):1231-1239.
Chiou S H, Winters I P, Wang J, et al. Pancreatic cancer modeling using retrograde viral vector delivery and in vivo CRISPR/Cas9-mediated somatic genome editing [J]. Genes Dev, 2015, 29(14):1576-1585.
[44]
Ran F, Hsu P, Lin C Y, et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity [J]. Cell, 2013, 154(6):1380-1389.
[45]
Shen B, Zhang W, Zhang J, et al. Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects. [J]. Nat Methods, 2014, 11(4): 399-402.
[46]
Tsai S Q, Wyvekens N, Khayter C, et al. Dimeric CRISPR RNA-guided Fokl nucleases for highly specific genome editing [J]. Nat Biotechno, 2014, 32(6):569-576.
2020, Vol. 31 
